Oral semaglutide demonstrated superior cardiometabolic outcomes relative to placebo and active comparators, including empaglifozin, in T2D.

Novo Nordisk's late stage diabetes candidate semaglutide ... more convenient weekly dosing schedule. Novo is also developing semaglutide in a patient-friendly pill form. Launched in 2015 ...

NPM-139 treatment resulted in nearly 20% placebo-adjusted weight loss from a single administration with expected once or twice-yearly dosing NPM ... containing semaglutide generated $25 billion ...

[O]ral semaglutide 14 mg (or flexible dosing, in PIONEER 7) was generally more effective at improving multiple cardiometabolic risk factors — including HbA 1c, [body weight], SBP, and LDL ...